JASPER THERAPEUTICS, INC. Restructuring and Related Cost, Expected Cost
JASPER THERAPEUTICS, INC. (JSPR) had Restructuring and Related Cost, Expected Cost of $2.30 million as of 2020-11-30, per its 10-Q filed 2022-11-10.
Discontinued › Notes
us-gaap:RestructuringAndRelatedCostExpectedCost1 · last filed 2022-11-10
- 2020-11-30: Restructuring and Related Cost, Expected Cost $2.30M.
| Period end | Restructuring and Related Cost, Expected Cost |
|---|---|
| 2020-11-30 | $2.30M 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |